New trial may spare thousands of breast cancer patients from chemo
NCT ID NCT07391774
First seen Feb 06, 2026 · Last updated Apr 29, 2026 · Updated 12 times
Summary
This study tests whether a combination of hormone therapy and a targeted drug (ribociclib) works as well as chemotherapy followed by the same hormone therapy and ribociclib for people with high-stage but low-risk breast cancer. About 1,978 postmenopausal women and men with estrogen receptor-positive, HER2-negative breast cancer will take part. The goal is to see if skipping chemotherapy can still prevent the cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE II BREAST CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.